Researchers at the University of Michigan have identified new targets for drugs that could potentially treat anthrax, the deadly infection caused by Bacillus anthracis.
Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had received shareholder approval to change its corporate name to Synthetic Biologics Inc.
Adeona Pharmaceuticals Inc. has swapped bosses as it continues testing new drugs for multiple sclerosis, fibromyalgia and Lou Gehrig’s disease. It’s also considering a new business focus and a name change.
A recent Van Andel Research Institute study published in the journal Science investigating the molecular structure and function of an essential plant hormone could profoundly change our understanding of a key cell process, and might ultimately lead to the development of new drugs for a variety of diseases.
Lycera Corp., a biopharmaceutical company creating innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research collaboration with Merck, triggering a milestone payment.
Drugs that could bring health to tens of thousands of kidney patients, cure osteoporosis and advance the battle against cancer were featured Wednesday on the second day of MichBio Expo, the annual meeting of the state’s biosciences business community.
Researchers from Michigan State University’s College of Human Medicine, Van Andel Research Institute and the Translational Genomics Research Institute are investigating a drug that has the potential to not only alleviate Parkinson’s symptoms but also halt the disease’s progression.
Lycera, a biopharmaceutical company and University of Michigan spinoff, plans to partner and collaborate with U-M faculty and students with a move to UM’s North Campus Research Complex.